Phase I study of high dose 5-fluorouracil and high dose leucovorin with low dose phosphonacetyl-l-aspartic acid in patients with advanced malignancies

Bach Ardalan, Kasi Stridhar, Rajender Reddy, Pasquale Benedetto, Stephen Richman, Stuart Waldman, Louise Morrell, Lynn Feun, Niramol Savaraj, Alan Livingstone

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Twenty-eight patients with refractory advanced malignancies were treated with a 24 hr infusion of 5-fluorouracil (5-FU), Leucovorin (LV), and N-(phosphonacetyl)-L-aspartic acid (PALA) weekly. Twenty-seven patients were evaluable for the assessment of toxicity and anti-tumor activity. PALA was administered as intravenous bolus over 15 min at a fixed dose, 250 mg/m2 24 hr before the start of 5-FU and LV infusions. 5-FU was initially administered at 750 mg/m2 and was incrementally increased to 2600 mg/m2. LV was administered in a fixed dose of 500 mg/m2 concurrently with 5-FU over a 24-hr period. The course was repeated weekly. Diarrhea, stomatitis, nausea, and vomiting were among dose-limiting toxic effects. Other toxicities observed were hand-foot syndrome, hair loss of scalp/eyelashes, overall weakness, rhinitis, and chemical conjunctivitis. Maximum tolerated dose (MTD) of 5-FU in this combination and schedule was 2600 mg/m2. Seven of 14 patients treated at 2600 mg/m2 were able to tolerate the chemotherapy on a weekly basis without interruption. The other seven patients required dose de-escalation, a majority of whom contained 5-FU at a dose of 2100 mg/m2. Twenty-three of 27 patients had been previously treated. Eight patients achieved a partial response, all of whom were previously treated, except three patients. A complete response was observed in a patient with pancreatic carcinoma, previously untreated. Overall response rate for the patients who were treated at the 5-FU dose of 2100 mg/m2 or 2600 mg/m2 is 9 of 18 patients (50%).

Original languageEnglish (US)
Pages (from-to)511-514
Number of pages4
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume22
Issue number3
DOIs
StatePublished - 1992

Keywords

  • FU/LV/PALA
  • Phase I

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Fingerprint Dive into the research topics of 'Phase I study of high dose 5-fluorouracil and high dose leucovorin with low dose phosphonacetyl-l-aspartic acid in patients with advanced malignancies'. Together they form a unique fingerprint.

  • Cite this